



07-05-02

RECEIVED  
AUG 1 2002

GP # 1615

TECH CENTER 1600/2000  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.**FEE TRANSMITTAL**  
**for FY 2002**

Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

(\$)

Complete if Known 09/835,501

Application Number

Filing Date

First Named Inventor

Examiner Name

Group Art Unit

Attorney Docket No.

Tyler Parr, Ph.D.

Robert M Joyner

1615

JUL 11 2002

RECEIVED

**METHOD OF PAYMENT (check all that apply)**☒ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☐ Deposit Account:Deposit Account Number  
Deposit Account Name

The Commissioner is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☐ Credit any overpayments☐ Charge any additional fee(s) during the pendency of this application☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity Small Entity

Fee Code (\$) Fee Code (\$)

101 740 201 370

106 330 206 165

107 510 207 255

108 740 208 370

114 160 214 80

Fee Description

Utility filing fee

Design filing fee

Plant filing fee

Reissue filing fee

Provisional filing fee

Fee Paid

SUBTOTAL (1) (\$)

**2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

Total Claims

Independent Claims

Multiple Dependent

Extra Claims

-20\*\* =

-3\*\* =

Fee from below

X

X

=

=

=

Large Entity Small Entity

Fee Code (\$) Fee Code (\$)

103 18 203 9

102 84 202 42

104 280 204 140

109 84 209 42

110 18 210 9

Fee Description

Claims in excess of 20

Independent claims in excess of 3

Multiple dependent claim, if not paid

\*\* Reissue independent claims over original patent

\*\* Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

\*\*or number previously paid, if greater; For Reissues, see above

**FEE CALCULATION (continued)****3. ADDITIONAL FEES**

Large Entity Small Entity

Fee Code (\$) Fee Code (\$)

105 130 205 65

127 50 227 25

139 130 139 130

147 2,520 147 2,520

112 920\* 112 920\*

113 1,840\* 113 1,840\*

115 110 215 55

116 400 216 200

117 920 217 460

118 1,440 218 720

128 1,960 228 980

119 320 219 160

120 320 220 160

121 280 221 140

138 1,510 138 1,510

140 110 240 55

141 1,280 241 640

142 1,280 242 640

143 460 243 230

144 620 244 310

122 130 122 130

123 50 123 50

126 180 126 180

581 40 581 40

146 740 246 370

149 740 249 370

179 740 279 370

169 900 169 900

Petition to institute a public use proceeding

Petition to revive - unavoidable

Petition to revive - unintentional

Utility issue fee (or reissue)

Design issue fee

Plant issue fee

Petitions to the Commissioner

Processing fee under 37 CFR 1.17(q)

Submission of Information Disclosure Stmt

Recording each patent assignment per property (times number of properties)

Filing a submission after final rejection (37 CFR § 1.129(a))

For each additional invention to be examined (37 CFR § 1.129(b))

Request for Continued Examination (RCE)

Request for expedited examination of a design application

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

Fee Description

Fee Paid

Surcharge - late filing fee or oath

Surcharge - late provisional filing fee or cover sheet

Non-English specification

For filing a request for *ex parte* reexamination

Requesting publication of SIR prior to Examiner action

Requesting publication of SIR after Examiner action

Extension for reply within first month

Extension for reply within second month

Extension for reply within third month

Extension for reply within fourth month

Extension for reply within fifth month

Notice of Appeal

Filing a brief in support of an appeal

Request for oral hearing

Petition to institute a public use proceeding

Petition to revive - unavoidable

Petition to revive - unintentional

Utility issue fee (or reissue)

Design issue fee

Plant issue fee

Petitions to the Commissioner

Processing fee under 37 CFR 1.17(q)

Submission of Information Disclosure Stmt

Recording each patent assignment per property (times number of properties)

Filing a submission after final rejection (37 CFR § 1.129(a))

For each additional invention to be examined (37 CFR § 1.129(b))

Request for Continued Examination (RCE)

Request for expedited examination of a design application

SUBTOTAL (3) (\$)

**SUBMITTED BY**

Name (Print/Type)

Signature

Tyler Parr, Ph.D.

TyParr

Registration No.

(Attorney/Agent)

Complete (if applicable)

Telephone

Date

(323) 865-0506

29 Jun 02

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**


Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

07/10/2002 ROSSMAN 00000070 09853501

180.00 DP

01 FC:126

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

### Complete if Known

Application Number	09/853,501
Filing Date	04/16/2001
First Named Inventor	Tyler Parr, PhD
Group Art Unit	1615
Examiner Name	Robert M. Joyner
Attorney Docket Number	

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		1. Kojima M., Hosoda H., Date Y., Makazato M., Matsuo H., Kangawa K. (1999) Ghrelin is a growth-hormone-releasing acylated peptide ... Nature 402:656-660	
		2. van Coevorden A., Mockel J., Laurent E., Kerkhofs M., L'Hermite-Baleriaux M., Decoster C., Neve P., van Cauter E. (1991) Neuroendocrine rhythms and sleep in aging men. Am J Physiol 260:E651-E661	
		3. Mendelson W.B., Lantigua R.A., Wyatt R.J., Gillin C., Jacobs L.S. (1981) Piperidine Enhances Sleep-Related and Insulin-Induced Growth Hormone Secretion. J. Clin. Endocrinol. Metab. 52:409-415	
		4. van Cauter E, FW Turek 1995 Endocrine and Other Biological Rhythms. In: DeGroot LJ (eds) Endocrinology 3rd Ed. Vol 3. W. B. Saunders Co., Philadelphia, pp 2487-2548	
		5. Muller EE 1995 Role of Neurotransmitters and Neuromodulators in the Control of Anterior Pituitary Hormone Secretion. In: DeGroot LJ (eds) Endocrinology, 3rd Edition, Vol. 1, pp 178-191	
		6. Wass JA, M Besser 1995 Tests of Pituitary Function. In: DeGroot LJ (eds) Endocrinology 3rd Ed. Vol. 1. W.B. Saunders Co., Philadelphia, pp 487-496	
		7. Parker M.L., hammond J.M., Daughaday W.H. (1967) The Arginine Provocative Test: An Aid in the Diagnosis of Hyposomatotropism. J Clin Endocrinol. Metab. 27:1129-1136	
		8. Corpas E., Blackman M.R., Robertson R., Scholfield D., Harman S.M. (1993) Oral Arginine-Lysine Does not Increase Growth Hormone or Insulin-like Growth Factor-I in Old Men. J. Gerontol. 48:M128-M133	
		9. Chin M.-Y., Kreutzer R.A. (1992) Acute Poisoning from g-Hydroxybutyrate in California. W J Med 156:380-384	
		10. Parr T. (1996) Insulin Exposure Controls the Rate of Mammalian Aging. Mech Ageing Dev 88:75-82	
		11. Parr T. (1997) Insulin Exposure and Aging Theory. Gerontology 43:182-200	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

AUG 21 2002

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Espoo Patent Reduction Act of 1980, persons are required to respond to a collection of information unless it contains a valid OMB control number.

TECH CENTER 1600/2900

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/853,501
		Filing Date	04/16/2001
		First Named Inventor	Tyler Parr
		Group Art Unit	1615
		Examiner Name	Robert M. Joyner
Attorney Docket Number			
Sheet	3	of	4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the book (if appropriate), journal, exposure, and unifying aging page number(s), publisher, city and/or country where published	T <sup>2</sup>
		12. Parr T.B. (2001) In: <i>Insulin Exposure and Unifying Aging</i> , pages 121-135	
		13. Parr T.B. (2001) A New Technique to Elevate of Night Time Growth Hormone Release and a Potential Growth Hormone Feedback Control Loop. <i>Med Hypotheses</i> 56:610-613	
		14. Paradies G., Ruggiero F.M., Petrosillo G., Gadaleta M.N., Quagliariello E. (1994) The Effect of Aging and Acetyl-L-carnitine on the Function and on the Lipid Composition.... <i>Ann. N. Y. Acad. Sci.</i> 717: 233-243	
		15. Buttgerit F., Brand M.D. (1995) A hierarchy of ATP-consuming processes in mammalian cells.. <i>Biochem. J.</i> 312:163-167	
		16. Castorina M., Ferraris L. (1994) Acetyl-L-carnitine affects aged brain receptor system in rodents. <i>Life Sci</i> 54:1205-1214	
		17. Ranke MB 1995 Growth Hormone Insufficiency: Clinical Features, Diagnosis, and Therapy. In: DeGroot LJ (eds) <i>Endocrinology</i> 3rd Ed.. W. B. Saunders Co., Philadelphia, pp	
		18. Besset A., Bonardet A., Roundouin G., Descommps B., Passouant P. (1982) Increase in sleep related GH and Prl secretion after chronic agrinine aspartate administration in man. <i>Acta Endocrinol</i> 99:18-23	
		19. Spagnoli A., Lucca U., Menasce G., Bandera L., Cizza G., Forloni G., Tettamanti M., Frattura L., Tiraboschi P., Comelli M., Senin U., Longo A., Petrini A., Brambilla G., Belloni A., Negri C., Cavazzuti F., Salsi A., Calogero P., Parma E., Stramba-Bidiale M., Vitali S., Andreoni G., Inzoli M.R., Santus G., Caregnato R., Peruzza M., Favaretto M., Bozeglav C., Alberoni M., Ed Leo D., Serraiotto L., Baiocchi A., Sciccia S., Culotta P., Ieracitano D. (1991) Long-term acetyl-L-carnitine treatment in Alzheimer's disease. <i>Neurology</i> 41:1726-1732	
		20. Bowman B.A. (1992) Acetyl-carnitine and Alzheimer's disease. <i>Nutr Rev</i> 50:142-144	
		21. Pettegrew J.W., Klunk W.E., Panchalingam K., Kanfer J.N., McClure R.J. (1995) Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. <i>Neurobiol Aging</i> 16:1-4	
		22. Goa K.L., Brogden R.N. (1987) L-Carnitine A Preliminary Review of its Pharmacokinetics, and its Therapeutic use in Ischemic Cardiac Diseases and Primary and Secondary Carnitine Deficiencies.... <i>Drugs</i> 34:1-24	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TECH CENTER 1600/2900

RECEIVED

JUL 11 2002

RECEIVED

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.